Next Article in Journal
MiRNAs in the Peri-Implantation Period: Contribution to Embryo–Maternal Communication in Pigs
Next Article in Special Issue
Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement
Previous Article in Journal
Recombination Pattern Characterization via Simulation Using Different Maize Populations
Previous Article in Special Issue
Beta3-Tubulin Is Critical for Microtubule Dynamics, Cell Cycle Regulation, and Spontaneous Release of Microvesicles in Human Malignant Melanoma Cells (A375)
Open AccessArticle

Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study

1
A.Li.Sa., Liguria Region Health Authority, 16121 Genoa, Italy
2
Pathology Unit, Galliera Hospital, 16128 Genoa, Italy
3
Office of the Scientific Director, Galliera Hospital, 16128 Genoa, Italy
4
Medical Oncology Unit, Galliera Hospital, 16128 Genoa, Italy
5
Gynecology Program, European Institute of Oncology, 20141 Milan, Italy
6
School of Medicine and Surgery, University Milan Bicocca, 20126 Milan, Italy
7
Barts School of Medicine, Queen Mary University of London, London E1 4NS, UK
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2020, 21(6), 2227; https://doi.org/10.3390/ijms21062227
Received: 14 February 2020 / Revised: 16 March 2020 / Accepted: 18 March 2020 / Published: 23 March 2020
(This article belongs to the Special Issue Cancer Prevention with Molecular Target Therapies)
Objective: Although endometrial cancer (EC) is a hormone dependent neoplasm, there are no recommendations for the determination of steroid hormone receptors in the tumor tissue and no hormone therapy has ever been assessed in the adjuvant setting. The purpose of this study was to explore the effect of adjuvant aromatase inhibitors (AIs) on progression-free survival (PFS) and overall survival (OS) in patients with early stage and steroid receptors-positive EC. Methods: We retrospectively analyzed clinical and pathological factors in 73 patients with high-risk (49.3%) or low-risk (50.7%) stage I (n = 71) or II (n = 2) endometrial cancer who received by their preference after counseling either no treatment (reference group) or AI. Prognostic factors were well balanced between groups. Expression of estrogen receptor (ER), progesterone receptor (PgR), and Ki-67 index was correlated with clinical outcomes. Results: Univariate and multivariate Cox proportional regression analyses, adjusted for age, grade, stage, depth of myometrial invasion, lymphovascular space invasion, BMI, ER, PgR and Ki-67 labeling index levels, showed that PFS and OS had a trend to be longer in patients receiving AI than in the reference group HR= 0.23 (95% CI; 0.04–1.27) for PFS and HR= 0.11 (95% CI; 0.01–1.36) for OS. Conclusion: Compared with no treatment, AI exhibited a trend toward a benefit on PFS and OS in patients with early stage hormone receptor-positive EC. Given the exploratory nature of our study, randomized clinical trials for ER/PgR positive EC patients are warranted to assess the clinical benefit of AI and the potential predictive role of steroid receptors and Ki-67. View Full-Text
Keywords: endometrial cancer; steroid receptors; aromatase inhibitors; progression free survival; overall survival endometrial cancer; steroid receptors; aromatase inhibitors; progression free survival; overall survival
Show Figures

Figure 1

MDPI and ACS Style

Paleari, L.; Rutigliani, M.; Siri, G.; Provinciali, N.; Colombo, N.; Decensi, A. Aromatase Inhibitors as Adjuvant Treatment for ER/PgR Positive Stage I Endometrial Carcinoma: A Retrospective Cohort Study. Int. J. Mol. Sci. 2020, 21, 2227.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop